No Data
Exagen Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Increased Its FY24 Revenue Outlook Above Estimates.
Express News | Exagen Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results and Increased Its FY24 Revenue Outlook Above Estimates
There's No Escaping Exagen Inc.'s (NASDAQ:XGN) Muted Revenues Despite A 38% Share Price Rise
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Maintains Target Price $7
Exagen's Strong Q2 Performance and Promising Outlook Merit a Buy Rating
Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript
The Exagen Inc. (NASDAQ:XGN) Annual Results Are Out And Analysts Have Published New ForecastsNo Data
